Biopeople

Award winners

Award winners

19.02.2013 - Three researchers – one from the UK and two from Germany – have been awarded the Louis-Jeantet prize for Medicine.

Michael Stratton, Chief of the Wellcome Trust Sanger Institute in Hinxton, UK, and the two German biochemists Peter Hegemann, Berlin, and Georg Nagel, Würzburg (photo), will receive a prize money of CHF700,000. Stratton got the prize, of which CHF75,000 is for personal use, for his work aimed at understanding the genetic causes of human cancer. He discovered the roles of the BRCA2 and BRAF genes in breast and skin cancers. Hegemann and Nagel, who share the prize, pioneered the field of optogenetics, a technique to control gene expression by switching light on and off. Namely, they discovered ion channels that can be activated by light.

28.02.2013 Cécile Miles has joined Prosonix plc (Oxford, UK) as the firm's new Chief Business Officer (CBO).

She comes to Prosonix from the former generics specialist Watson Group (now Actavis). Prior to that, Miles held senior management positions at Ark Therapeutics, Pliva and Ranbaxy Laboratories Ltd. She also spent several years in a variety of commercial roles at Fisons plc.

19.03.2013 Geneviève Almouzni will be handed over the prestigous FEBS | EMBO Women in Science Award in July.

The deputy director of the Institut Curie in Paris, France has been recognized with €10,000 for her outstanding research in the field  of epigenetics, especially the role histones and chromatin assembly in gene activity control. Almouzni started her professional career in the laboratory of Marcel Méchali, where she managed to identify critical molecular mechanisms regulating DNA replication and chromatin assembly. After completing a CNRS research assistant position in 1991, she moved to the lab of Alan Wolffe, a scientist who turned the chromatin field into a mainstream research subject. In 1994, Geneviève Almouzni was awarded a junior investigator grant of the CNRS and started as a junior group leader at the Institut Curie. Recently, she received an ERC Advanced Investigator grant and obtained a Laboratory of Excellence grant from the French Ministry of Research. 

14.03.2013 Contract biomanufacturer Rentschler Biotechnologie GmbH (Laupheim, Germany) has named Frank Ternes as Chief Business Officer.

The former Senior VP Biopharma Contract Manufacturing at Boehringer Ingelheim will lead the planning, development and execution of all business development, sales & marketing and project management activities at Rentschler. The master in economics brings in more than 25 years of experience from Operations and Technology.

12.03.2013 Zealand Pharma has appointed Agneta Svedberg as successor to Senior Vice President and Chief Operating Officer.

John Hyttel, who is retiring after 14 years with the company, The Master of Business Administration joins the Danish firm from Cantargia AB, a Swedish biotech company, where she has held a position as Chief Executive Officer. Agneta Svedberg brings in more than 20 years of experience in drug development from different leadership functions in both biotech and big pharma companies, including more than ten years with Genmab A/S in Copenhagen, where she was Global Head of Clinical Development and held various senior management positions.  Prior to that, she was Head of Clinical Development (Europe) at Oxigene Europe AB and held managerial positions at Pharmacia & Upjohn AB in Sweden. Agneta Svedberg holds a M.Sc. in Radiation Physics from Lund University.

21.03.2013 Shirley Knauer and Dr. Michael Hiller have been awarded the €50,000 German Life Science Award from the German Society for Biochemistry and Molecular Biology and Roche Diagnostics.

Shirley Knauer was honoured for her research on cancer cell migration and the mechanisms of chemo- and radiation therapy resistance. Her work has been focused on two cancer targets: Survivin and die Taspase 1. Dr. Michael Hiller war awarded for his comparative bioinformatic analyes of the genomes ranging from humans to monkeys and other animal species. He defined a gene defect that has no consequence in animals but causes severe liver damage in man. 

Photo: Claudia Geipel

25.03.2013 Swiss Cytos Biotechnology Ltd (Schlieren) has strengthened its Board with two appointments.

Matthias Alder will become Executive Vice President for Corporate Development and Legal Affairs and Cheryl Lassen will follow Philipp Mueller as Vice President for Clinical Development, who will retire at the end of March 2013. Matthias Alder brings in more than 19 years of experience in the pharmaceutical and biotechnology sector. He comes in from Micromet, where he was Senior VP Administration, General Counsel and Secretary. Previousy he worked with Cooley LLP, as in-house counsel at Ciba-Geigy and Novartis. Cheryl Lassen, MD, joins bringing a wealth of clinical development experience, with particular expertise in respiratory diseases. Dr. Lassen joins Cytos from Novartis where she was Program Leader. In her 20 year career, she has worked on a multitude of clinical development programs and in medical affairs in the UK and in South Africa for companies including Bristol Myers Squibb, Abbott Laboratories and Pharmacia.

22.03.2013 London-based start-up CoCo Therapeutics Ltd has named Dr Steve Butcher as Chief Operating Officer.

The founder and Scientific Director of the Fujisawa Institute of Neuroscience will lead the development of the firm’s Alzheimer’s programmes. After having held management positions of increasing responsibility at Pharmacia AB he had several senior positions in biotechnology companies, including CSO at BioImage A/S and COO at TopoTarget A/S.

09.04.2013 Wellington Partners has appointed Stuart M. Essig as a new Venture Partner for its life sciences investment team.

Essig comes from global medical device company Integra LifeSciences Holdings Corporation where he was CEO and Chairman of the Board from 1997.  Before joining Integra, Mr. Essig supervised the medical technology practice at Goldman, Sachs & Co. as a Managing Director. Mr. Essig brings ten years of broad health care experience at Goldman Sachs, serving as a senior merger and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients. Mr. Essig also serves on the Board of Directors of St. Jude Medical Corporation and ADVAMED, the Advanced Medical Technology Association. Mr. Essig received an A.B. degree from the Woodrow Wilson School of Public and International Affairs at Princeton University and an M.B.A. and a Ph.D. degree in Financial Economics from the University of Chicago, Booth School of Business.

05.04.2013 German Mologen AG has hired Alfredo Zurlo for the newly created position as Chief Medical Officer (CMO).

The oncologist, with more than 13 years of clinical expertise, take the post at the beginning of April. Dr Zurlo will be responsible for the clinical development of Mologen’s oncology candidate drugs MGN1703 and MGN1601. Zurlo has worked with Mologen as Senior Medical Advisor since 2012. Prior to that he worked for 8 years with Roche, as Medical Director of Oncology and Senior International Medical Leader.

03.04.2013 Swiss Basilea Ltd has proposed Martin Nicklasson as the successor to Chairman Werner Henrich, whose term will end in June.

Dr Nicklasson is a high-profile pharmaceutical business professional with longstanding operational and board experience. Born in 1955, the Swedish pharmacist is Associate Professor at the Department of Pharmaceutics, University of Uppsala. Dr Nicklasson has held numerous leadership and executive positions in commercial operations and drug development at AstraZeneca Plc. He was the President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and serves as a Board Member in a number of biotech companies in Europe and the US.

Vorherige Seite2/8Nächste Seite

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events